摘要
目的探讨国产替罗非班在急性冠脉综合征(ACS)经皮血运重建治疗中的疗效及安全性。方法共入选48例ACS患者,其中男27例,女21例。患者均符合目前冠心病介入治疗适应证。国产盐酸替罗非班按0.4μg.kg-1.min-1剂量静脉滴注,术后肝素或低分子肝素减为半量,阿司匹林及氯吡格雷按ACS的常规剂量使用;观察用药后4.5d和30.0d内任何原因的死亡、新的心肌梗死及顽固性心绞痛的发生情况。结果用药后4.5d和30.0d内均未见新的心肌梗死、顽固性心绞痛发生,亦无死亡发生,3例(6.2%)无复流或慢血流患者经应用替罗非班后恢复正常血流。4例(8.3%)发生轻中度出血,无严重出血发生。血小板聚集率用药后明显的下降,与用药前比较差别有统计学意义(P<0.05)。结论国产替罗非班是一高选择性、抗血小板临床疗效好、安全性高的药物。
Objective To probe into safety and efficacy of domestic tirofiban in percutaneous revascularization in patients with acute coronary syndrome （ACS）. Methods Forty - eight ACS patients （27 males, 21 females ） , who were in line with the current coronary intervention treatment indications, were enrolled and given intravenous drips of domestic tirofiban hydro- chloride in a dose of 0.4μg· kg^-1· min^-1. After surgery, heparin or low- molecular- weight heparin was reduced by half, and aspirin and clopidogrel were given by conventional - dose use ; death for any reason, new myocardial infarction and refractory angina pectoris were observed within 4. 5 and 30. 0 days after use of tirofiban. Results After 4. 5 and 30. 0 days of medication, no more myocardial infarction and refractory angina pectoris occurred, nor did any deaths; 3 patients with no reflow or with slow blood flow recovered to normality after application of tirofiban （6. 2% ） , 4 presented with mild - moderate bleeding （8.3%）, but no severe bleeding occurred. Platelet aggregation rate reduced significantly after medication （ P 〈 0.05 ）. Conclusion Domestic Tirofiban is a safe drug with high selection and a good anti -platelet effect.
出处
《中国全科医学》
CAS
CSCD
2008年第14期1280-1281,共2页
Chinese General Practice
